Nosaka, T.; Murata, Y.; Akazawa, Y.; Tanaka, T.; Takahashi, K.; Naito, T.; Matsuda, H.; Ohtani, M.; Imamura, Y.; Nakamoto, Y.
Programmed Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor and Monitor of Response to Atezolizumab plus Bevacizumab Treatment in Patients with Hepatocellular Carcinoma. Cancers 2024, 16, 1785.
https://doi.org/10.3390/cancers16091785
AMA Style
Nosaka T, Murata Y, Akazawa Y, Tanaka T, Takahashi K, Naito T, Matsuda H, Ohtani M, Imamura Y, Nakamoto Y.
Programmed Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor and Monitor of Response to Atezolizumab plus Bevacizumab Treatment in Patients with Hepatocellular Carcinoma. Cancers. 2024; 16(9):1785.
https://doi.org/10.3390/cancers16091785
Chicago/Turabian Style
Nosaka, Takuto, Yosuke Murata, Yu Akazawa, Tomoko Tanaka, Kazuto Takahashi, Tatsushi Naito, Hidetaka Matsuda, Masahiro Ohtani, Yoshiaki Imamura, and Yasunari Nakamoto.
2024. "Programmed Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor and Monitor of Response to Atezolizumab plus Bevacizumab Treatment in Patients with Hepatocellular Carcinoma" Cancers 16, no. 9: 1785.
https://doi.org/10.3390/cancers16091785
APA Style
Nosaka, T., Murata, Y., Akazawa, Y., Tanaka, T., Takahashi, K., Naito, T., Matsuda, H., Ohtani, M., Imamura, Y., & Nakamoto, Y.
(2024). Programmed Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor and Monitor of Response to Atezolizumab plus Bevacizumab Treatment in Patients with Hepatocellular Carcinoma. Cancers, 16(9), 1785.
https://doi.org/10.3390/cancers16091785
